Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 18
SponsorYang Li
About this trial
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
Eligibility criteria
Qualifiers
Pathological diagnosis basis of malignant tumor；
Patients not more than 18 years old;
Patient has either germline or somatic p53 mutations, which was shown to be partially/completely restored to function by ATO in in vitro experiments (http://www.rescuep53.net);
There are measurable lesions;
Disqualifiers
None
Trial design
Treatments tested in this trial
- Arsenic trioxide
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Yang Li
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor institution
Ruijin Hospital
Collaborator
Source ClinicalTrials.gov